Despite the challenges 2020 has presented, CX-011 is on schedule to enter clinical trials for mild to moderate osteoarthritis in mid-2021. Following successful scale up and validation, sufficient quantities of the therapeutic candidate were produced under strict Good Manufacturing Practices (GMP) guidelines to support the trial next year. In parallel, CarthroniX received positive regulatory feedback

HEALTH Magazine announced its picks of best new skincare products for 2020, and Heraux Molecular Anti-Inflammaging Serum was included in this elite selection. Highly curated by Heath’s beauty editors, this influential award recognizes the unique technology present in Heraux and the impact this product has in the luxury beauty category.